Compare Stocks: JSPR, GANX, CNTB, and PMVP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.10 +1.9%	$2.02	$1.05 ▼ $3.82	$67.38M	-0.23	492,195 shs	382,803 shs
GANX Gain Therapeutics	$1.77 -0.8%	$1.84	$1.53 ▼ $4.34	$77.03M	0.2	731,715 shs	228,704 shs
JSPR Jasper Therapeutics	$0.61 -0.5%	$0.69	$0.32 ▼ $2.69	$20.17M	3.04	847,746 shs	29,320 shs
PMVP PMV Pharmaceuticals	$1.32 -1.1%	$1.29	$1.02 ▼ $1.88	$70.30M	1.37	492,719 shs	55,717 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-15.63%	-51.57%	-54.62%	-31.65%
GANX Gain Therapeutics	0.00%	+0.85%	+0.56%	-10.10%	-0.56%
JSPR Jasper Therapeutics	0.00%	-1.41%	-12.95%	+45.09%	-75.34%
PMVP PMV Pharmaceuticals	0.00%	-11.33%	+9.02%	+3.10%	-10.14%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CNTB Connect Biopharma	$1.10 +1.9%	$2.02	$1.05 ▼ $3.82	$67.38M	-0.23	492,195 shs	382,803 shs
GANX Gain Therapeutics	$1.77 -0.8%	$1.84	$1.53 ▼ $4.34	$77.03M	0.2	731,715 shs	228,704 shs
JSPR Jasper Therapeutics	$0.61 -0.5%	$0.69	$0.32 ▼ $2.69	$20.17M	3.04	847,746 shs	29,320 shs
PMVP PMV Pharmaceuticals	$1.32 -1.1%	$1.29	$1.02 ▼ $1.88	$70.30M	1.37	492,719 shs	55,717 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CNTB Connect Biopharma	0.00%	-15.63%	-51.57%	-54.62%	-31.65%
GANX Gain Therapeutics	0.00%	+0.85%	+0.56%	-10.10%	-0.56%
JSPR Jasper Therapeutics	0.00%	-1.41%	-12.95%	+45.09%	-75.34%
PMVP PMV Pharmaceuticals	0.00%	-11.33%	+9.02%	+3.10%	-10.14%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CNTB Connect Biopharma	2.75	Moderate Buy	$6.86	534.92% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	321.35% Upside
JSPR Jasper Therapeutics	2.29	Hold	$7.33	1,103.96% Upside
PMVP PMV Pharmaceuticals	2.80	Moderate Buy	$4.33	225.81% Upside

Current Analyst Ratings Breakdown

Latest JSPR, GANX, CNTB, and PMVP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/24/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/22/2026	CNTB Connect Biopharma	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$5.00
9/16/2026	CNTB Connect Biopharma	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $6.00
9/15/2026	CNTB Connect Biopharma	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/14/2026	CNTB Connect Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/9/2026	PMVP PMV Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/4/2026	PMVP PMV Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
9/3/2026	CNTB Connect Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/31/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CNTB Connect Biopharma	$60K	1,133.46	N/A	N/A	$0.75 per share	1.44
GANX Gain Therapeutics	$50K	1,553.58	N/A	N/A	$0.48 per share	3.71
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$0.15 per share	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	$1.97 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CNTB Connect Biopharma	-$55.48M	-$1.19	N/A	N/A	N/A	N/A	-165.41%	-121.58%	11/11/2026 (Estimated)
GANX Gain Therapeutics	-$20.16M	-$0.50	N/A	N/A	N/A	N/A	-161.59%	-118.36%	11/11/2026 (Estimated)
JSPR Jasper Therapeutics	-$75.80M	-$1.59	N/A	N/A	N/A	N/A	-884.17%	-143.83%	11/9/2026 (Estimated)
PMVP PMV Pharmaceuticals	-$77.74M	-$1.42	N/A	N/A	N/A	N/A	-78.11%	-70.13%	11/11/2026 (Estimated)

Latest JSPR, GANX, CNTB, and PMVP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	JSPR Jasper Therapeutics	-$0.2678	-$0.10	+$0.1678	-$0.10	N/A	N/A
8/14/2026	Q2 2026	PMVP PMV Pharmaceuticals	-$0.3875	-$0.34	+$0.0475	-$0.34	N/A	N/A
8/12/2026	Q2 2026	CNTB Connect Biopharma	-$0.3149	-$0.27	+$0.0449	-$0.27	$0.74 million	$2.75 million
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CNTB Connect Biopharma	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
PMVP PMV Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CNTB Connect Biopharma	0.01	2.37	2.37
GANX Gain Therapeutics	0.02	4.36	4.36
JSPR Jasper Therapeutics	N/A	1.48	1.47
PMVP PMV Pharmaceuticals	N/A	7.70	7.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CNTB Connect Biopharma	58.72%
GANX Gain Therapeutics	11.97%
JSPR Jasper Therapeutics	79.85%
PMVP PMV Pharmaceuticals	90.20%

Insider Ownership

Company	Insider Ownership
CNTB Connect Biopharma	22.60%
GANX Gain Therapeutics	4.15%
JSPR Jasper Therapeutics	3.90%
PMVP PMV Pharmaceuticals	10.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CNTB Connect Biopharma	64	62.97 million	48.74 million	Optionable
GANX Gain Therapeutics	21	43.64 million	41.83 million	Optionable
JSPR Jasper Therapeutics	22	33.28 million	31.98 million	Optionable
PMVP PMV Pharmaceuticals	54	53.46 million	48.03 million	Optionable

JSPR, GANX, CNTB, and PMVP Headlines

Recent News About These Companies

Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?

September 16, 2026 | zacks.com

Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), PMV Pharmaceuticals (PMVP) and Tyra Bioscience (TYRA)

September 9, 2026 | theglobeandmail.com

PMV Pharma Names Herman Chief Commercial Officer Ahead Of Rezatapopt Filing

September 9, 2026 | rttnews.com

PMV Pharma appoints Philip Herman as CCO

September 9, 2026 | thepharmaletter.comT

Brokers Issue Forecasts for PMVP Q3 Earnings

September 9, 2026 | marketbeat.com

PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer

September 8, 2026 | finance.yahoo.com

919,818 Shares in PMV Pharmaceuticals, Inc. $PMVP Acquired by BlackRock Inc.

September 7, 2026 | marketbeat.com

PMV Pharmaceuticals stock gains as biotech peers advance

September 5, 2026 | ad-hoc-news.deA

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Receives Consensus Rating of "Moderate Buy" from Brokerages

September 4, 2026 | marketbeat.com

PMV Pharmaceuticals (NASDAQ:PMVP) Given "Buy" Rating at HC Wainwright

September 4, 2026 | marketbeat.com

PMV Pharmaceuticals, Inc.: PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

September 1, 2026 | finanznachrichten.de

PMV Pharma Posts Interim Phase 2 PYNNACLE Ovarian Cancer Data; Prices $50.8 Mln Offering; Stock Down

September 1, 2026 | rttnews.com

PMV Pharmaceuticals Reports Updated Rezatapopt Ovarian Cancer Data, Commences Offering

September 1, 2026 | finance.yahoo.com

PMV Pharma Prices $50.8 Million Public Offering of Common Stock, Pre-Funded Warrants and Accompanying Warrants

August 31, 2026 | quiverquant.comQ

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

August 31, 2026 | globenewswire.com

PMV Pharma Announces Proposed Public Offering of Securities

August 31, 2026 | globenewswire.com

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

August 31, 2026 | globenewswire.com

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

August 19, 2026 | zacks.com

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

August 14, 2026 | globenewswire.com

PMV Pharmaceuticals, Inc.

August 13, 2026 | edition.cnn.com

PMV Pharmaceuticals Earnings Estimates, EPS & Revenue | NASDAQ:PMVP

June 25, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, GANX, CNTB, and PMVP Company Descriptions

Connect Biopharma NASDAQ:CNTB

$1.08 0.00 (0.00%)

As of 11:33 AM Eastern

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.

Gain Therapeutics NASDAQ:GANX

$1.76 -0.02 (-0.84%)

As of 11:33 AM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Jasper Therapeutics NASDAQ:JSPR

$0.61 0.00 (-0.51%)

As of 11:33 AM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

PMV Pharmaceuticals NASDAQ:PMVP

$1.32 -0.02 (-1.13%)

As of 11:33 AM Eastern

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JSPR, GANX, CNTB, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JSPR, GANX, CNTB, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JSPR, GANX, CNTB, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, GANX, CNTB, and PMVP Company Descriptions

Connect Biopharma NASDAQ:CNTB

Gain Therapeutics NASDAQ:GANX

Jasper Therapeutics NASDAQ:JSPR

PMV Pharmaceuticals NASDAQ:PMVP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JSPR, GANX, CNTB, and PMVP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JSPR, GANX, CNTB, and PMVP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JSPR, GANX, CNTB, and PMVP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JSPR, GANX, CNTB, and PMVP Company Descriptions

Connect Biopharma NASDAQ:CNTB

Gain Therapeutics NASDAQ:GANX

Jasper Therapeutics NASDAQ:JSPR

PMV Pharmaceuticals NASDAQ:PMVP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools